Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
80% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.93
CRMD's Equity to Asset is ranked higher than
89% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRMD: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.75 Max: 0.95
Current: 0.93
-1.36
0.95
F-Score: 5
Z-Score: 9.47
M-Score: -0.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6087.87
CRMD's Operating margin (%) is ranked lower than
91% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. CRMD: -6087.87 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s Operating margin (%) Range Over the Past 10 Years
Min: -245750  Med: -125230.03 Max: -4710.05
Current: -6087.87
-245750
-4710.05
Net-margin (%) -6079.04
CRMD's Net-margin (%) is ranked lower than
91% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. CRMD: -6079.04 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s Net-margin (%) Range Over the Past 10 Years
Min: -456650  Med: -233735.85 Max: -10821.69
Current: -6079.04
-456650
-10821.69
ROE (%) -92.00
CRMD's ROE (%) is ranked lower than
79% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. CRMD: -92.00 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s ROE (%) Range Over the Past 10 Years
Min: -678.23  Med: -416.80 Max: -155.37
Current: -92
-678.23
-155.37
ROA (%) -82.84
CRMD's ROA (%) is ranked lower than
84% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CRMD: -82.84 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s ROA (%) Range Over the Past 10 Years
Min: -507.14  Med: -196.95 Max: -116.99
Current: -82.84
-507.14
-116.99
ROC (Joel Greenblatt) (%) -37395.93
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. CRMD: -37395.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -73563.64  Med: -42147.06 Max: -35270.59
Current: -37395.93
-73563.64
-35270.59
EBITDA Growth (3Y)(%) 14.70
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CRMD: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.7  Med: -13.00 Max: 14.7
Current: 14.7
-66.7
14.7
EPS Growth (3Y)(%) 17.90
CRMD's EPS Growth (3Y)(%) is ranked higher than
76% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CRMD: 17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: -15.70 Max: 17.9
Current: 17.9
-68.5
17.9
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CRMD Guru Trades in Q4 2014

Paul Singer 781,440 sh (unchged)
» More
Q1 2015

CRMD Guru Trades in Q1 2015

Jim Simons 47,600 sh (New)
Paul Singer 1,500,200 sh (+91.98%)
Paul Singer 1,500,200 sh (+91.98%)
» More
Q2 2015

CRMD Guru Trades in Q2 2015

Paul Singer 1,500,200 sh (unchged)
Jim Simons Sold Out
» More
Q3 2015

CRMD Guru Trades in Q3 2015

Paul Singer 2,373,694 sh (+58.23%)
Paul Singer 1,500,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.55
CRMD's P/B is ranked higher than
74% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CRMD: 1.55 )
Ranked among companies with meaningful P/B only.
CRMD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 61.5
Current: 1.55
0
61.5
P/S 165.43
CRMD's P/S is ranked lower than
99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. CRMD: 165.43 )
Ranked among companies with meaningful P/S only.
CRMD' s P/S Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 10793.6
Current: 165.43
0
10793.6
Current Ratio 13.62
CRMD's Current Ratio is ranked higher than
83% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CRMD: 13.62 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 3.22 Max: 20.26
Current: 13.62
0.1
20.26
Quick Ratio 13.38
CRMD's Quick Ratio is ranked higher than
83% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. CRMD: 13.38 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 3.05 Max: 19.89
Current: 13.38
0.1
19.89
Days Inventory 514.24
CRMD's Days Inventory is ranked lower than
96% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. CRMD: 514.24 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 147.24 Max: 222.19
Current: 514.24
72.28
222.19
Days Sales Outstanding 167.74
CRMD's Days Sales Outstanding is ranked lower than
88% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. CRMD: 167.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 154.5  Med: 259.75 Max: 365
Current: 167.74
154.5
365
Days Payable 1.00
CRMD's Days Payable is ranked lower than
98% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. CRMD: 1.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 730.82  Med: 1214.67 Max: 1698.51
Current: 1
730.82
1698.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.62
CRMD's Price/Net Cash is ranked higher than
87% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CRMD: 1.62 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s Price/Net Cash Range Over the Past 10 Years
Min: 2.01  Med: 4.00 Max: 35.14
Current: 1.62
2.01
35.14
Price/Net Current Asset Value 1.55
CRMD's Price/Net Current Asset Value is ranked higher than
88% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. CRMD: 1.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.93  Med: 3.81 Max: 31.74
Current: 1.55
1.93
31.74
Price/Tangible Book 1.55
CRMD's Price/Tangible Book is ranked higher than
84% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CRMD: 1.55 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.93  Med: 3.81 Max: 31.74
Current: 1.55
1.93
31.74
Price/Projected FCF 5.93
CRMD's Price/Projected FCF is ranked lower than
69% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. CRMD: 5.93 )
Ranked among companies with meaningful Price/Projected FCF only.
CRMD' s Price/Projected FCF Range Over the Past 10 Years
Min: 7.37  Med: 9.95 Max: 12.52
Current: 5.93
7.37
12.52
Earnings Yield (Greenblatt) (%) -88.18
CRMD's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CRMD: -88.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1325.05  Med: 0.00 Max: 0
Current: -88.18
-1325.05
0

More Statistics

Revenue(Mil) $0
EPS $ -0.60
Beta-0.42
Short Percentage of Float13.62%
52-Week Range $1.15 - 10.40
Shares Outstanding(Mil)35.38

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 0 1 3 7
EPS($) -0.66 -0.70 -0.50 -0.30
EPS without NRI($) -0.66 -0.70 -0.50 -0.30

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
The Life Sciences Report's 2016 Small-Cap Biotech Watchlist Jan 28 2016
CorMedix to Present at National Kidney Foundation® 2016 Spring Clinical Meetings Jan 21 2016
CORMEDIX INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jan 19 2016
CorMedix to Present at Biotech Showcase™ 2016 Jan 06 2016
The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist Dec 22 2015
CorMedix, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 14 2015
CorMedix Announces Enrollment and Dosing of First Patient in Phase 3 Neutrolin® Trial in... Dec 14 2015
CORMEDIX INC. Financials Dec 08 2015
CORMEDIX INC. Files SEC form 8-K, Other Events Dec 01 2015
How Is Smart Money Trading CorMedix Inc. (CRMD)? Nov 23 2015
CorMedix Inc. to Present at Salomon Bio Investment and Leadership Conference Nov 13 2015
CORMEDIX INC. Files SEC form 10-Q, Quarterly Report Nov 12 2015
CORMEDIX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Nov 09 2015
CorMedix, Inc. to Announce Third Quarter 2015 Results on November 12, 2015 Nov 04 2015
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 30 2015
Pacific Premier Bancorp, Inc. Announces the Appointment of New Director Oct 07 2015
CorMedix Inc. Abstracts Highlighting the Economic Burden of Central Venous Catheter Complications to... Oct 05 2015
CorMedix, Inc. Earnings Q2, 2015 Oct 02 2015
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK